Noxa determines localization and stability of MCL-1 and consequently ABT-737 sensitivity in small cell lung cancer
W Nakajima1, M A Hicks1, N Tanaka2
1Department of Oral and Craniofacial Molecular Biology, School of Dentistry, Massey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA.
Abstract:
The sensitivity to ABT-737, a prototype BH3 mimetic drug, varies in a broad range in small cell lung cancer (SCLC) cells. We have previously shown that the expression of Noxa, a BH3-only pro-apoptotic BCL-2 family protein, is the critical determinant of ABT-737 sensitivity. We show here that Noxa regulates the localization and stability of MCL-1, an anti-apoptotic member, which results in modulating ABT-737 sensitivity. Mutations in Noxa within the BH3 domain, the carboxyl terminus mitochondrial targeting domain, or of ubiquitinated lysines not only change the localization and stability of Noxa itself but also affect the mitochondrial localization and phosphorylation/ubiquitination status of MCL-1 and consequently modulate sensitivity to ABT-737. Results of studies utilizing these mutant proteins indicate that Noxa recruits MCL-1 from the cytosol to the mitochondria. Translocation of MCL-1 initiates its phosphorylation and subsequent ubiquitination, which triggers proteasome-mediated degradation. The precise regulatory mechanisms of Noxa/MCL-1 expression and stability could provide alternative targets to modulate apoptosis induced by BH3 mimetic drugs or other chemotherapeutic reagents.
Insights
Noxa protein levels critically determine sensitivity to ABT-737 in small cell lung cancer (SCLC). Noxa regulates MCL-1 stability, impacting drug response and offering potential therapeutic targets.
Area of Science:
- Molecular Biology
- Cancer Research
- Cell Death Pathways
Background:
- Sensitivity to ABT-737, a BH3 mimetic, varies in small cell lung cancer (SCLC).
- Noxa, a BH3-only protein, is a key determinant of ABT-737 sensitivity in SCLC.
- MCL-1 is an anti-apoptotic protein that influences drug response.
Purpose of the Study:
- To investigate the role of Noxa in regulating MCL-1 localization and stability.
- To understand how Noxa-MCL-1 interactions modulate ABT-737 sensitivity in SCLC.
- To identify potential therapeutic targets for enhancing BH3 mimetic efficacy.
Main Methods:
- Utilizing mutant Noxa proteins with alterations in key functional domains (BH3, mitochondrial targeting, ubiquitination sites).
- Assessing changes in protein localization (cytosolic vs. mitochondrial) and post-translational modifications (phosphorylation, ubiquitination) of Noxa and MCL-1.
- Evaluating the impact of these molecular changes on ABT-737 sensitivity in SCLC cells.
Main Results:
- Noxa regulates the localization and stability of the anti-apoptotic protein MCL-1.
- Mutations in Noxa affect its own localization and stability, as well as MCL-1's mitochondrial localization and modification status.
- Noxa recruits MCL-1 to the mitochondria, initiating its phosphorylation, ubiquitination, and proteasomal degradation, thereby modulating ABT-737 sensitivity.
Conclusions:
- Noxa-mediated regulation of MCL-1 stability is a critical mechanism influencing ABT-737 sensitivity in SCLC.
- Understanding Noxa/MCL-1 dynamics offers insights into overcoming resistance to BH3 mimetics.
- Targeting Noxa/MCL-1 interactions may provide novel therapeutic strategies for SCLC treatment.
